CLB

15.71

6.88% -1.16

Vorhandelsmarkt: 15.70 -0.01 -0.06%

Core Laboratories Inc (CLB)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$16.87

Offen:

$16.05

24-Stunden-Volumen:

577.35K

Relative Volume:

1.49

Marktkapitalisierung:

$731.51M

Einnahmen:

$526.52M

Nettoeinkommen (Verlust:

$32.53M

KGV:

23.32

EPS:

0.6738

Netto-Cashflow:

$23.29M

1W Leistung:

-3.56%

1M Leistung:

-10.59%

6M Leistung:

+25.78%

1J Leistung:

+0.96%

1-Tages-Spanne:

$15.45

$16.76

1-Wochen-Bereich:

$15.45

$17.07

52-Wochen-Spanne:

$9.72

$20.36

Core Laboratories Inc Stock (CLB) Company Profile

Firmenname

Core Laboratories Inc

Sektor

Energy (245)

Branche

Oil & Gas Equipment & Services (50)

Telefon

713-328-2673

Adresse

6316 WINDFERN ROAD, HOUSTON

Mitarbeiter

3,500

Twitter

@corelabcompany

Nächster Verdiensttermin

2026-04-22

Neueste SEC-Einreichungen

CLB's Discussions on Twitter

Compare CLB vs SLB, BKR, HAL, TS, FTI

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CLB Core Laboratories Inc	15.71	731.51M	526.52M	32.53M	23.29M	0.6738
SLB Slb Ltd	50.51	75.82B	35.69B	3.45B	4.54B	2.3617
BKR Baker Hughes Company	63.49	62.74B	27.73B	2.62B	2.54B	2.605
HAL Halliburton Co	38.11	31.92B	22.18B	1.29B	1.67B	1.5088
TS Tenaris S A Adr	57.23	28.89B	12.00B	1.98B	2.02B	2.7949
FTI Technipfmc Plc	70.16	28.06B	9.93B	967.10M	1.45B	2.3076

Core Laboratories Inc Stock (CLB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-12	Hochstufung	Citigroup	Sell → Neutral
2023-06-30	Herabstufung	Citigroup	Neutral → Sell
2023-04-18	Herabstufung	BofA Securities	Neutral → Underperform
2023-01-09	Hochstufung	BofA Securities	Underperform → Neutral
2022-10-07	Hochstufung	Citigroup	Sell → Neutral
2022-09-26	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2022-04-18	Herabstufung	Piper Sandler	Neutral → Underweight
2021-10-18	Herabstufung	BofA Securities	Neutral → Underperform
2021-07-09	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-06-14	Herabstufung	Citigroup	Neutral → Sell
2020-12-18	Herabstufung	JP Morgan	Neutral → Underweight
2020-11-11	Bestätigt	Cowen	Market Perform
2020-10-13	Hochstufung	BofA Securities	Underperform → Neutral
2020-09-29	Hochstufung	ABN Amro	Sell → Hold
2020-07-16	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2020-04-13	Hochstufung	Scotiabank	Sector Perform → Sector Outperform
2020-03-09	Herabstufung	BofA/Merrill	Buy → Underperform
2020-03-09	Herabstufung	Evercore ISI	Outperform → In-line
2020-01-31	Bestätigt	Cowen	Market Perform
2020-01-30	Fortgesetzt	Johnson Rice	Buy
2020-01-14	Eingeleitet	Bernstein	Mkt Perform
2020-01-02	Herabstufung	Stifel	Buy → Hold
2019-12-31	Bestätigt	Cowen	Market Perform
2019-07-10	Hochstufung	BofA/Merrill	Neutral → Buy
2019-02-25	Hochstufung	Tudor Pickering	Hold → Buy
2018-12-19	Herabstufung	Credit Suisse	Outperform → Neutral
2018-12-11	Herabstufung	JP Morgan	Overweight → Neutral
2018-11-16	Hochstufung	Guggenheim	Neutral → Buy
2018-11-01	Hochstufung	ABN Amro	Sell → Buy
2018-10-29	Bestätigt	Cowen	Market Perform

Alle ansehen

Core Laboratories Inc Aktie (CLB) Neueste Nachrichten

Mar 24, 2026

History Review: Is Core Laboratories Inc backed by strong institutional buying2026 Rallies & Weekly Market Pulse Alerts - baoquankhu1.vn

Mar 24, 2026

Core Laboratories (NYSE:CLB) Shares Gap DownHere's Why - MarketBeat

Mar 24, 2026

Here’s Why Maintaining a Hold Position Is Suitable for Core Laboratories Shares at This Time - Bitget

Mar 24, 2026

Here's Why Hold Strategy Is Apt for Core Laboratories Stock for Now - Yahoo Finance

Mar 24, 2026

Core Labs cuts Q1 guidance, citing impact of Middle East war (CLB:NYSE) - Seeking Alpha

Mar 23, 2026

CORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCE - Bitget

Mar 23, 2026

Core Laboratories cuts Q1 2026 guidance on Middle East conflict - Investing.com

Mar 23, 2026

Core Laboratories (CLB) Shares Fall 5% Following Preliminary Q1 Results - GuruFocus

Mar 23, 2026

Core Laboratories Cuts Q1 2026 Guidance Amid Mideast Turmoil - TipRanks

Mar 23, 2026

Core Laboratories Sees Q1 Adj EPS $0.05-$0.07... - Benzinga

Mar 23, 2026

Core Laboratories Expects Q1 2026 Revenue An... - Benzinga

Mar 23, 2026

Core revises Q1 2026 guidance, now sees revenue $119M-$123M and EPS $0.05-$0.07 - TradingView

Mar 23, 2026

Core Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026 - marketscreener.com

Mar 23, 2026

Core Laboratories (NYSE: CLB) trims Q1 2026 guidance amid Middle East turmoil - Stock Titan

Mar 23, 2026

Core Laboratories Inc. 2025 Annual Report – Business Overview, Strategy, Operations, and Climate Initiatives - Minichart

Mar 23, 2026

Core Laboratories 10-K: $526.5M Revenue, $0.65 Diluted EPS - TradingView

Mar 23, 2026

Mar 21, 2026

CWA Asset Management Group LLC Makes New Investment in Core Laboratories Inc. $CLB - MarketBeat

Mar 21, 2026

Mar 20, 2026

Core Laboratories (NYSE: CLB) outlines global operations, 2025 revenue and key risk exposures - Stock Titan

Mar 20, 2026

Mar 18, 2026

Core Laboratories Revises Financials Following Tax Review () - aktiencheck.de

Mar 18, 2026

Mar 17, 2026

Core Laboratories Inc. Files Form 8-K/A SEC Report for February 2026 – Company Information and Filing Details - Minichart

Mar 17, 2026

Core Laboratories (NYSE: CLB) trims 2025 EPS after $4.2M tax adjustment - Stock Titan

Mar 17, 2026

Mar 16, 2026